Novo Seeds co-led a $61.7m round for the oncology therapy developer to help commercialise research originating at University of Copenhagen and Rigshospitalet.

Adcendo, a Denmark-based antibody drug conjugate (ADC) developer based on research at University of Copenhagen and Rigshospitalet, completed a €51m ($61.7m) series A round yesterday co-led by pharmaceutical firm Novo through its Novo Seeds subsidiary. Venture capital firm Ysios Capital co-led the round, which also featured investment management firm RA Capital Management, VC firm HealthCap…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.